Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Inify Laboratories AB Audit Report / Information 2022

Apr 12, 2023

6123_10-k_2023-04-12_b2c8a063-f7eb-4a07-9ff9-9af4d64446b1.html

Audit Report / Information

Open in viewer

Opens in your device viewer

Inify Laboratories - Årsredovisning 2022

Inify Laboratories - Årsredovisning 2022

Stockholm - 12 April, 2023 - Inify Laboratories, ett företag som tillhandahåller

helt digitaliserade laboratorietjänster inom prostatacancerdiagnostik,

presenterar sin årsredovisning för räkenskapsåret som avslutades den 31 december

Årsredovisningen bifogas detta pressmeddelande och finns även tillgänglig på

företagets hemsida: www.inify.com.

Tryckta exemplar av årsredovisningen distribueras på begäran som skickas till e

-post: [email protected].

För frågor, vänligen kontakta CFO Ann-Charlotte Linderoth på e-post: ann

[email protected] eller på: [email protected]

About Inify Laboratories

Inify Laboratories is currently building and establishing an ultramodern

laboratory that will provide cancer diagnostics within histopathology. Designed

from scratch, it uses a fully digital, standardized and AI-supported workflow to

optimize quality and shorten response times, initially within prostate cancer.

The first laboratory, located at Campus Solna Sweden, is estimated to start

offering services to both public and private healthcare providers before summer

The company originates from ContextVision, with nearly 40 years of experience

within digital imaging for medical applications and became independent through a

spin-off in February 2022. The company, based in Sweden, is listed on Euronext

Growth Oslo under the ticker INIFY.

Denna information är föremål för upplysningskraven enligt 5-12 § i den Norska

lagen om värdepappershandel.